Now Enrolling

IIT-2017-10117

...

A pilot study for Allergan's intravenous antibiotic, Dalvance® (dalbavancin), administered every 14 days for the treatment of Septic Arthritis (2 infusions) and / or Osteomyelitis (3 infusions)
Read More at Contagion Live
Read More at ClinicalTrials.gov
Read More at Contagion Live
Read More at Oxford Academic

Top of Page

Closed to Enrollment

C4591031

...

A Phase 3 Master Protocol to evaluate additional dose(s) of BNt162b2 in healthy individuals previously vaccinated with BNt162b2

Read More
Read More
September 16 Updated Informed Consent Disclosure

Top of Page

J2W-MC-PYAB

...

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of neutralizing antibody bamlanivimab (LY-COV555) in Participants with Mild to Moderate COVID-19 Illness following protocals LY3819253, LY3832479 and other study arms (patients must have a positive COVID-19 nasal swab test within 72 hours of enrolling)

Read More at Lilly
Read More
Read More

Top of Page

C4591001

...

A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, Immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.

Read more at Pfizer News
Read More at Medical Xpress
Read More at Clinical Trails Arena

Updated General Eligibility Criteria
2021 Final Informed Consent Disclosure

Top of Page

GS-US-200-4625

...

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance

Read More
Read More

Top of Page

CP101

Finch Therapeutics

A Phase III Clinical Trial Studying CP101 for Recurrent C. Difficile, With a Rollover Open-Label Option.

Read More at Finch Therapeutics
Read More
Read More

Top of Page

B5091007

...

A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine In Adults 50 Years of Age and Older

Read More
Read More at Clover Trial

Top of Page

ViiV 209035

...

ViiV 209035 - This is a “roll-over” study including only current patients from another trial: A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Participated in Study LAI116482

Top of Page

ViiV 207966

...

207966 (ATLAS 2) - A study evaluating the efficacy, safety, and tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every 4 or 8 weeks in Virologically Suppressed HIV-1-infected adults.

Read More

Top of Page